Literature DB >> 22895181

The role of S6K1 in ER-positive breast cancer.

Marina K Holz1.   

Abstract

The 40S ribosomal S6 kinase 1 (S6K1) is a conserved serine/threonine protein kinase that belongs to the AGC family of protein kinases, which also includes Akt and many others. S6K1 is the principal kinase effector downstream of the mammalian target of rapamycin complex 1 (mTORC1). S6K1 is sensitive to a wide range of signaling inputs, including growth factors, amino acids, energy levels and hypoxia. S6K1 relays these signals to regulate a growing list of substrates and interacting proteins in control of oncogenic processes, such as cell growth and proliferation, cell survival and apoptosis and cell migration and invasion. Several lines of evidence suggest an important role for S6K1 in estrogen receptor (ER)-positive breast cancer. S6K1 directly phosphorylates and activates ERα. Furthermore, S6K1 expression is estrogenically regulated. Therefore, hyperactivation of mTORC1/S6K1 signaling may be closely related to ER-positive status in breast cancer and may be utilized as a marker for prognosis and a therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895181      PMCID: PMC3466514          DOI: 10.4161/cc.21194

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  78 in total

Review 1.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers.

Authors:  L Savelyeva; A Claas; I Matzner; P Schlag; W Hofmann; S Scherneck; B Weber; M Schwab
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

4.  Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

Authors:  R A Campbell; P Bhat-Nakshatri; N M Patel; D Constantinidou; S Ali; H Nakshatri
Journal:  J Biol Chem       Date:  2001-01-03       Impact factor: 5.157

5.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Authors:  K Yu; L Toral-Barza; C Discafani; W G Zhang; J Skotnicki; P Frost; J J Gibbons
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

6.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

Authors:  M Bärlund; F Forozan; J Kononen; L Bubendorf; Y Chen; M L Bittner; J Torhorst; P Haas; C Bucher; G Sauter; O P Kallioniemi; A Kallioniemi
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

7.  Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer.

Authors:  O Monni; M Barlund; S Mousses; J Kononen; G Sauter; M Heiskanen; P Paavola; K Avela; Y Chen; M L Bittner; A Kallioniemi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

8.  17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes.

Authors:  G J Wu; C S Sinclair; J Paape; J N Ingle; P C Roche; C D James; F J Couch
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

Review 9.  Understanding the mechanisms of aromatase inhibitor resistance.

Authors:  William R Miller; Alexey A Larionov
Journal:  Breast Cancer Res       Date:  2012-01-19       Impact factor: 6.466

10.  Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.

Authors:  D M Maruani; T N Spiegel; E N Harris; A S Shachter; H A Unger; S Herrero-González; M K Holz
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

View more
  31 in total

1.  Autophagy modulates cell migration and β1 integrin membrane recycling.

Authors:  Véronique Tuloup-Minguez; Ahmed Hamaï; Anne Greffard; Valérie Nicolas; Patrice Codogno; Joëlle Botti
Journal:  Cell Cycle       Date:  2013-09-09       Impact factor: 4.534

2.  Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Authors:  Melissa Sokolosky; William H Chappell; Kristin Stadelman; Stephen L Abrams; Nicole M Davis; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

3.  Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.

Authors:  Anya Alayev; Rachel S Salamon; Yang Sun; Naomi S Schwartz; Chenggang Li; Jane J Yu; Marina K Holz
Journal:  Am J Respir Cell Mol Biol       Date:  2015-11       Impact factor: 6.914

4.  The combination of rapamycin and resveratrol blocks autophagy and induces apoptosis in breast cancer cells.

Authors:  Anya Alayev; Sara Malka Berger; Melissa Y Kramer; Naomi S Schwartz; Marina K Holz
Journal:  J Cell Biochem       Date:  2015-03       Impact factor: 4.429

Review 5.  From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?

Authors:  Victoria Shang Wu; Noriko Kanaya; Chiao Lo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-05-18       Impact factor: 4.292

Review 6.  Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.

Authors:  Jin Zhang; Qianying Wang; Qing Wang; Jiangran Cao; Jiafu Sun; Zhengmao Zhu
Journal:  Cell Mol Life Sci       Date:  2019-08-30       Impact factor: 9.261

Review 7.  Unconventional Estrogen Signaling in Health and Disease.

Authors:  Christina L Faltas; Kira A LeBron; Marina K Holz
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

Review 8.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

Review 9.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

10.  Targeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.

Authors:  Aditi Bhattacharya; Maggie Mamcarz; Caitlin Mullins; Ayesha Choudhury; Robert G Boyle; Daniel G Smith; David W Walker; Eric Klann
Journal:  Neuropsychopharmacology       Date:  2015-12-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.